Vertex drops mRNA cystic fibrosis program over 'tolerability' issues
Vertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy, after facing challenges delivering the genetic medicine similar to those that have troubled other parts of the field. The Boston-based company
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · US
- [HEALTH] Return on investment of community health workers in the United States: a systematic review.
- [CONFLICT] 'Heil Hitler': NYC synagogues, homes vandalized in spate of antisemitic graffiti
- [TECH] Anthropic and OpenAI establish joint ventures on Wall Street to accelerate enterprise AI adoption
- [TECH] US deploys jets, helicopters to support escort operation
- [CONFLICT] 👠Top athlete looks at Met Gala 2026
- [CONFLICT] Secret Service on scene of shooting in Washington, says one person shot by law enforcement